Hepatocyte nuclear factor-1-beta (HNF1B) is a transcription factor and putative biomarker of solid tumours. Recently, we have revealed a variety of HNF1B mRNA alternative splicing variants (ASVs) with unknown, but potentially regulatory, functions. The aim of our work was to quantify the most common variants and compare their expression in tumour and non-tumour tissues of the large intestine, prostate, and kidney. The HNF1B mRNA variants 3p, Δ7, Δ7-8, and Δ8 were expressed across all the analysed tissues in 28.2-33.5%, 1.5-2%, 0.8-1.7%, and 2.3-6.9% of overall HNF1B mRNA expression, respectively, and occurred individually or in combination. The quantitative changes of ASVs between tumour and non-tumour tissue were observed for the large intestine (3p, Δ7-8), prostate (3p), and kidney samples (Δ7). Decreased expression of the overall HNF1B mRNA in the large intestine and prostate cancer samples compared with the corresponding non-tumour samples was observed (p = 0.019 and p = 0.047, respectively). The decreased mRNA expression correlated with decreased protein expression in large intestine carcinomas (p < 0.001). The qualitative and quantitative pattern of the ASVs studied by droplet digital PCR was confirmed by next-generation sequencing, which suggests the significance of the NGS approach for further massive evaluation of the splicing patterns in a variety of genes.

Institute of Biology and Medical Genetics 1st Faculty of Medicine Charles University and General University Hospital Prague Albertov 4 128 00 Prague 2 Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague Kateřinská 32 121 08 Prague 2 Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Studničkova 2 12800 Prague 2 Czech Republic

Zobrazit více v PubMed

Cereghini S. Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 1996;10:267–282. doi: 10.1096/fasebj.10.2.8641560. PubMed DOI

Barbacci E, et al. HNF1beta/TCF2 mutations impair transactivation potential through altered co-regulator recruitment. Hum. Mol. Genet. 2004;13:3139–3149. doi: 10.1093/hmg/ddh338. PubMed DOI

Bartu M, et al. The role of HNF1B in tumorigenesis of solid tumours: A review of current knowledge. Folia Biol. (Praha) 2018;64:71–83. PubMed

Yu DD, Guo SW, Jing YY, Dong YL, Wei LX. A review on hepatocyte nuclear factor-1beta and tumor. Cell Biosci. 2015;5:58. doi: 10.1186/s13578-015-0049-3. PubMed DOI PMC

Suzuki E, et al. Transcriptional upregulation of HNF-1beta by NF-kappaB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression. Lab Investig. 2015;95:962–972. doi: 10.1038/labinvest.2015.73. PubMed DOI

Tsuchiya A, et al. Expression profiling in ovarian clear cell carcinoma: Identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 2003;163:2503–2512. doi: 10.1016/S0002-9440(10)63605-X. PubMed DOI PMC

Carithers LJ, et al. A novel approach to high-quality postmortem tissue procurement: The GTEx project. Biopreserv. Biobank. 2015;13:311–319. doi: 10.1089/bio.2015.0032. PubMed DOI PMC

Debiais-Delpech C, et al. Expression patterns of candidate susceptibility genes HNF1beta and CtBP2 in prostate cancer: Association with tumor progression. Urol. Oncol. 2014;32:426–432. doi: 10.1016/j.urolonc.2013.09.006. PubMed DOI

Elliott KS, et al. Evaluation of association of HNF1B variants with diverse cancers: Collaborative analysis of data from 19 genome-wide association studies. PLoS One. 2010;5:e10858. doi: 10.1371/journal.pone.0010858. PubMed DOI PMC

Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Investig. 2004;113:913–923. doi: 10.1172/JCI20032. PubMed DOI PMC

Janky R, et al. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer. 2016;16:632. doi: 10.1186/s12885-016-2540-6. PubMed DOI PMC

Kondratyeva LG, Chernov IP, Zinovyeva MV, Kopantzev EP, Sverdlov ED. Expression of master regulatory genes of embryonic development in pancreatic tumors. Dokl. Biochem. Biophys. 2017;475:250–252. doi: 10.1134/S1607672917040020. PubMed DOI

Spurdle AB, et al. Genome-wide association study identifies A common variant associated with risk of endometrial cancer. Nat. Genet. 2011;43:451–454. doi: 10.1038/ng.812. PubMed DOI PMC

Yamamoto S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum. Pathol. 2007;38:1074–1080. doi: 10.1016/j.humpath.2006.12.018. PubMed DOI

Bartu M, et al. Expression, epigenetic, and genetic changes of HNF1B in colorectal lesions: An analysis of 145 cases. Pathol. Oncol. Res. 2020;26:2337–2350. doi: 10.1007/s12253-020-00830-2. PubMed DOI

Bartu M, et al. Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours. Sci. Rep. 2020;10:17151. doi: 10.1038/s41598-020-74059-z. PubMed DOI PMC

Dundr P, et al. HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study. Sci. Rep. 2020;10:14365. doi: 10.1038/s41598-020-71427-7. PubMed DOI PMC

Nemejcova K, et al. A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma. Oncol. Lett. 2021;21:185. doi: 10.3892/ol.2021.12446. PubMed DOI PMC

Hojny J, et al. Identification of novel HNF1B mRNA splicing variants and their qualitative and semi-quantitative profile in selected healthy and tumour tissues. Sci. Rep. 2020;10:6958. doi: 10.1038/s41598-020-63733-x. PubMed DOI PMC

Ryan M, et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 2016;44:1018–1022. doi: 10.1093/nar/gkv1288. PubMed DOI PMC

Nemejcova K, et al. Expression, epigenetic and genetic changes of HNF1B in endometrial lesions. Pathol. Oncol. Res. 2016;22:523–530. doi: 10.1007/s12253-015-0037-2. PubMed DOI

Buchner A, et al. Downregulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis. Urology. 2010;76(507):e506–e511. doi: 10.1016/j.urology.2010.03.042. PubMed DOI

Harries LW, Brown JE, Gloyn AL. Species-specific differences in the expression of the HNF1A, HNF1B and HNF4A genes. PLoS One. 2009;4:e7855. doi: 10.1371/journal.pone.0007855. PubMed DOI PMC

Harries LW, Perry JR, McCullagh P, Crundwell M. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer. 2010;10:315. doi: 10.1186/1471-2407-10-315. PubMed DOI PMC

Huggett JF, et al. The digital MIQE guidelines: Minimum information for publication of quantitative digital PCR experiments. Clin. Chem. 2013;59:892–902. doi: 10.1373/clinchem.2013.206375. PubMed DOI

Hojny J, et al. Multiplex PCR and NGS-based identification of mRNA splicing variants: Analysis of BRCA1 splicing pattern as a model. Gene. 2017;637:41–49. doi: 10.1016/j.gene.2017.09.025. PubMed DOI

R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2020). https://www.R-project.org

Walker LC, et al. Comprehensive assessment of BARD1 messenger ribonucleic acid splicing with implications for variant classification. Front. Genet. 2019;10:1139. doi: 10.3389/fgene.2019.01139. PubMed DOI PMC

Robinson JT, et al. Integrative genomics viewer. Nat. Biotechnol. 2011;29:24–26. doi: 10.1038/nbt.1754. PubMed DOI PMC